Article
Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Molecular oncology - 1 Nov 2016
Hallett Robin M, Seong Alex B K, Kaplan David R, Irwin Meredith S
Abstract excerpt
BACKGROUND: In the pediatric cancer neuroblastoma (NB), patients are stratified into low, intermediate or high-risk subsets based in part on MYCN amplification status. While MYCN amplification in general predicts unfavorable outcome, no clinical or genomic factors have been identified that predict outcome within these cohorts of high-risk patients. In particular, it is currently not possible at diagnosis to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.